Maki M, Matsukawa N, Yuasa H, Otsuka Y, Yamamoto T, Akatsu H, Okamoto T, Ueda R, Ojika K. Decreased expression of hippocampal cholinergic neurostimulating peptide precursor protein mRNA in the hippocampus in Alzheimer disease. J Neuropathol Exp Neurol. 2002 Feb;61(2):176-85. PubMed.
Recommends
Please login to recommend the paper.
Comments
�
Hippocampal cholinergic neurostimulating peptide precursor protein, found in this study to be reduced in the hippocampus in AD, is also known as phosphatidylethanolamine-binding protein (PEBP).
Kazuki et al find (1) that 21q22.2-qter carries a gene responsible for downregulation of PEBP in the DS mouse model.
It seems of interest that PEBP exerts inhibitory activity against serine proteases including thrombin, neuropsin, and chymotrypsin.(2)
In view of the report by Shimizu-Okabe and colleagues of increased neuropsin, a gene involved in learning and memory, in the AD hippocampus (3) and the studies finding thrombin and alpha1-antichymotrypsin in amyloid plaques, might we suspect upregulation of this PEBP inhibitory gene in AD?
References:
Kazuki Y, Kimura M, Nishigaki R, Kai Y, Abe S, Okita C, Shirayoshi Y, Schulz TC, Tomizuka K, Hanaoka K, Inoue T, Oshimura M. Human chromosome 21q22.2-qter carries a gene(s) responsible for downregulation of mlc2a and PEBP in Down syndrome model mice. Biochem Biophys Res Commun. 2004 Apr 30;317(2):491-9. PubMed.
Hengst U, Albrecht H, Hess D, Monard D. The phosphatidylethanolamine-binding protein is the prototype of a novel family of serine protease inhibitors. J Biol Chem. 2001 Jan 5;276(1):535-40. PubMed.
Shimizu-Okabe C, Yousef GM, Diamandis EP, Yoshida S, Shiosaka S, Fahnestock M. Expression of the kallikrein gene family in normal and Alzheimer's disease brain. Neuroreport. 2001 Aug 28;12(12):2747-51. PubMed.
Make a Comment
To make a comment you must login or register.